Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population

Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction

(2018) Ylenia Ingrasciotta et al.   DRUG SAFETY

Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs

(2018) Joshua J. Gagne et al.   DRUG SAFETY

The FDA Sentinel Initiative — An Evolving National Resource

(2018) Richard Platt et al.   NEW ENGLAND JOURNAL OF MEDICINE

The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference

(2017) Judy Crespi-Lofton et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

The FDA's sentinel initiative-A comprehensive approach to medical product surveillance

(2016) R Ball et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit Managers

(2015) Benjamin P. Falit et al.   HEALTH AFFAIRS

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

(2008)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION